Mate small biotech companies buying back shares never ends well. They raised the money at a higher price. This money is need to advance the pipeline. Spending on a buy back just means they will need to raise more money again sooner. And maybe at a lower price, so more dilution etc. The best thing CHM can do is advance the pipeline and show they have drugs that work. And they need every cent to do that. They have attacked disease with no SOC. They have drugs with very little competition. CarT against solid tumours! NK cells!
Give the market the data it needs and the share price will sort itself out. If that data cant be found it will be time to look for another investment.
Being 100% focused on pipeline development is where we need the BOD to be at. With the expansion trial, and planned registration trial they seem to be doing just that. The market will join in when the pathway becomes less scary.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)